Pharvaris charts approval course for swelling disorder drug on Phase III win
Phase 3positivedeucrictibant XRPositive
AI Analysis
Summary
Pharvaris announced positive Phase III trial results for deucrictibant XR, an oral treatment for hereditary angioedema, and plans to pursue regulatory approval as competition in the HAE market intensifies.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Phase III trial met endpoints for orally administered deucrictibant XR
Importance:8/10
Sentiment:
0.75
Phase 3approvalHAEoral therapy
Related Companies
Read the original article
Published by Clinical Trials Arena on September 9, 2026 10:33 AM